Full Info Institutions/PIs

Selected Publications of Principle Investigator

1. Yuen H, Mackinnon A, Hartmann J, Amminger G, Markulev C, Lavoie S, Schäfer M, Polari A, Mossaheb N, Schlögelhofer M, Smesny S, Hickie I, Berger G, Chen E, de Haan L, Nieman D, Nordentoft M, Riecher-Rössler A, Verma S, Thompson A, Yung A, McGorry P, Nelson B (2018) Dynamic prediction of transition to psychosis using joint modelling Schizophr Res, 202: 333-340
2. Nelson B, Amminger G, Yuen H, Markulev C, Lavoie S, Schäfer M, Hartmann J, Mossaheb N, Schlögelhofer M, Smesny S, Hickie I, Berger G, Chen E, de Haan L, Nieman D, Nordentoft M, Riecher-Rössler A, Verma S, Thompson A, Yung A, McGorry P (2018) NEURAPRO: a multi-centre RCT of omega-3 polyunsaturated fatty acids versus placebo in young people at ultra-high risk of psychotic disorders—medium-term follow-up and clinical course NPJ Schizophr, 4 (1): 11
3. Mossaheb N, Schäfer M, Schlögelhofer M, Klier C, Smesny S, McGorry P, Berger M, Amminger G (2018) Predictors of longer-term outcome in the Vienna omega-3 high-risk study Schizophr Res, 193: 168-172
4. Hinterbuchinger B, Litvan Z, Meyer E, Friedrich F, Kaltenboeck A, Gruber M, König D, Sueßenbacher S, Mossaheb N (2018) Psychotic-like experiences in esoterism: A twilight zone? Schizophr Res, 193: 240-243
5. McGorry P, Nelson B, Markulev C, Yuen H, Schäfer M, Mossaheb N, Schlögelhofer M, Smesny S, Hickie I, Berger G, Chen E, de Haan L, Nieman D, Nordentoft M, Riecher-Rössler A, Verma S, Thompson A, Yung A, Amminger G (2017) Effect of ω-3 Polyunsaturated Fatty Acids in Young People at Ultrahigh Risk for Psychotic Disorders JAMA Psychiatry, 74 (1): 19
6. Hartmann J, McGorry P, Schmidt S, Amminger G, Yuen H, Markulev C, Berger G, Chen E, de Haan L, Hickie I, Lavoie S, McHugh M, Mossaheb N, Nieman D, Nordentoft M, Riecher-Rössler A, Schäfer M, Schlögelhofer M, Smesny S, Thompson A, Verma S, Yung A, Nelson B (2017) Opening the Black Box of Cognitive-Behavioural Case Management in Clients with Ultra-High Risk for Psychosis Psychother Psychosom, 86 (5): 292-299
7. McHugh M, McGorry P, Yuen H, Hickie I, Thompson A, de Haan L, Mossaheb N, Smesny S, Lin A, Markulev C, Schloegelhofer M, Wood S, Nieman D, Hartmann J, Nordentoft M, Schäfer M, Amminger G, Yung A, Nelson B (2017) The Ultra-High-Risk for psychosis groups: Evidence to maintain the status quo Schizophr Res,
8. Mossaheb N, Schloegelhofer M, Kaufmann R, Werneck-Rohrer S, Zehetmayer S, Malik F, Khawar R, Chaudry H, Amminger G, Klier C, Aschauer H (2013) Duration of untreated psychosis in a high-income versus a low- and middle-income region Aust N Z J Psychiatry, 47 (12): 1176-1182
9. Mossaheb N, Schäfer M, Schlögelhofer M, Klier C, Cotton S, McGorry P, Amminger G (2013) Effect of omega-3 fatty acids for indicated prevention of young patients at risk for psychosis: When do they begin to be effective? Schizophr Res, 148 (1-3): 163-167
10. Mossaheb N, Becker J, Schaefer M, Klier C, Schloegelhofer M, Papageorgiou K, Amminger G (2012) The Community Assessment of Psychic Experience (CAPE) questionnaire as a screening-instrument in the detection of individuals at ultra-high risk for psychosis Schizophr Res, 141 (2-3): 210-214